PL2301962T3 - Wynalazek dotyczący glp-1 i eksendyny - Google Patents

Wynalazek dotyczący glp-1 i eksendyny

Info

Publication number
PL2301962T3
PL2301962T3 PL10012756T PL10012756T PL2301962T3 PL 2301962 T3 PL2301962 T3 PL 2301962T3 PL 10012756 T PL10012756 T PL 10012756T PL 10012756 T PL10012756 T PL 10012756T PL 2301962 T3 PL2301962 T3 PL 2301962T3
Authority
PL
Poland
Prior art keywords
glu
ser
gly
leu
ala
Prior art date
Application number
PL10012756T
Other languages
English (en)
Inventor
Marti Béhé
Thomas Behr
Martin Gotthardt
Burkhard Göke
Original Assignee
Philipps Univ Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philipps Univ Marburg filed Critical Philipps Univ Marburg
Publication of PL2301962T3 publication Critical patent/PL2301962T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
PL10012756T 2004-09-03 2005-08-26 Wynalazek dotyczący glp-1 i eksendyny PL2301962T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004043153A DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin
EP10012756.2A EP2301962B1 (de) 2004-09-03 2005-08-26 Erfindung betreffend GLP-1 und Exendin
EP05778889A EP1784422B1 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin

Publications (1)

Publication Number Publication Date
PL2301962T3 true PL2301962T3 (pl) 2014-05-30

Family

ID=35970651

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10012756T PL2301962T3 (pl) 2004-09-03 2005-08-26 Wynalazek dotyczący glp-1 i eksendyny
PL08020703T PL2070946T3 (pl) 2004-09-03 2005-08-26 Wynalazek dotyczący GLP-1 i eksendyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08020703T PL2070946T3 (pl) 2004-09-03 2005-08-26 Wynalazek dotyczący GLP-1 i eksendyny

Country Status (16)

Country Link
US (2) US8268781B2 (pl)
EP (3) EP2301962B1 (pl)
JP (1) JP5047795B2 (pl)
KR (1) KR101237152B1 (pl)
CN (3) CN102304179A (pl)
AT (1) ATE486090T1 (pl)
AU (1) AU2005279537C1 (pl)
BR (1) BRPI0515624A (pl)
CA (2) CA2797666A1 (pl)
DE (2) DE102004043153B4 (pl)
HR (1) HRP20110061T1 (pl)
MX (1) MX2007002455A (pl)
NO (1) NO20071592L (pl)
PL (2) PL2301962T3 (pl)
RU (3) RU2420536C2 (pl)
WO (1) WO2006024275A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606894A1 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
KR20110043766A (ko) * 2008-09-20 2011-04-27 고쿠리츠 다이가쿠 호진 교토 다이가쿠 췌도 이미징용 분자 프로브 전구체 및 그의 사용
WO2010043566A2 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem insulin und einem glp-1-agonisten
US8992886B2 (en) 2009-04-06 2015-03-31 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
KR101321461B1 (ko) * 2009-08-10 2013-10-29 아크레이 가부시키가이샤 췌도 이미징용 분자 프로브 및 그 전구체, 및 그들의 사용
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
JP5608867B2 (ja) 2009-09-30 2014-10-15 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
EP2510951B1 (en) 2009-12-10 2016-07-13 Kyoto University Molecular probe for imaging of pancreatic islet, and use thereof
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9278146B2 (en) 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
US9289516B2 (en) * 2011-03-09 2016-03-22 The General Hospital Corporation Imaging beta cell mass
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) * 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) * 2014-09-04 2016-03-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
LT3297653T (lt) * 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017102613A1 (en) 2015-12-14 2017-06-22 Sanofi Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals Inc formulações tamponadas de exendina (9-39)
WO2021198229A1 (en) 2020-03-31 2021-10-07 Antaros Medical Ab Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001144A1 (en) * 1989-07-20 1991-02-07 Sandoz Ltd Labeled polypeptide derivatives
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
WO1997046584A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
EP1056775B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
AU775063C (en) * 1999-04-30 2005-05-12 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
CA2623458A1 (en) * 1999-05-17 2000-11-23 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1246638B2 (en) * 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1546200A2 (en) * 2002-10-02 2005-06-29 Zealand Pharma A/S Stabilized exendin-4 compounds
WO2004037859A1 (ja) * 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1誘導体及びその経粘膜吸収型製剤

Also Published As

Publication number Publication date
EP2301962B1 (de) 2013-10-30
RU2486197C2 (ru) 2013-06-27
CN102358752A (zh) 2012-02-22
CN102304179A (zh) 2012-01-04
RU2010148446A (ru) 2012-06-10
HRP20110061T1 (hr) 2011-02-28
US20130095037A1 (en) 2013-04-18
RU2007112115A (ru) 2008-10-10
PL2070946T3 (pl) 2013-09-30
RU2010148447A (ru) 2012-06-10
EP2070946B1 (de) 2013-05-29
EP2070946A2 (de) 2009-06-17
CA2797666A1 (en) 2006-03-09
EP1784422A2 (de) 2007-05-16
JP2008511557A (ja) 2008-04-17
EP2301962A2 (de) 2011-03-30
DE102004043153B4 (de) 2013-11-21
NO20071592L (no) 2007-05-29
US8268781B2 (en) 2012-09-18
EP1784422B1 (de) 2010-10-27
KR20070093960A (ko) 2007-09-19
US20090180953A1 (en) 2009-07-16
WO2006024275A2 (de) 2006-03-09
BRPI0515624A (pt) 2008-07-29
DE502005010449D1 (de) 2010-12-09
CN101010340A (zh) 2007-08-01
EP2301962A3 (de) 2011-11-02
RU2420536C2 (ru) 2011-06-10
WO2006024275A3 (de) 2006-11-30
AU2005279537C1 (en) 2012-07-05
CA2578252A1 (en) 2006-03-09
KR101237152B1 (ko) 2013-03-04
JP5047795B2 (ja) 2012-10-10
DE102004043153A1 (de) 2006-03-23
ATE486090T1 (de) 2010-11-15
AU2005279537B2 (en) 2012-02-16
CN102358752B (zh) 2014-07-30
CN101010340B (zh) 2012-11-28
EP2070946A3 (de) 2009-09-09
AU2005279537A1 (en) 2006-03-09
RU2489443C2 (ru) 2013-08-10
MX2007002455A (es) 2007-10-10

Similar Documents

Publication Publication Date Title
PL2301962T3 (pl) Wynalazek dotyczący glp-1 i eksendyny
RU2019122785A (ru) Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
MX2021005835A (es) Compuestos co-agonistas de gip y glp-1.
PH12021550154A1 (en) Gip/glp1 co-agonist compounds.
NO20063436L (no) Intranasal administrasjon av glukose-regulerende peptider
RU2010101232A (ru) Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
ATE448247T1 (de) Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
HRP20020996B1 (en) Glucagon-like peptide-1 analogs
PE20220938A1 (es) Compuestos agonistas de gipr
EA200300644A1 (ru) Слитые белки glp-1
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
HK1135112A1 (en) Exendin fusion proteins
DK1523325T3 (da) Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
JP2004509079A5 (pl)
RU2012109553A (ru) Модифицированные вазоактивные интестинальные пептиды
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
MX2023002906A (es) Agonistas duales glp-1/gip.
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
MX2022016032A (es) Agonistas dobles de glp-1/gip de accion prolongada.
Kühn-Wache et al. Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos